行情

INFI

INFI

Infinity制药
NASDAQ

实时行情|Nasdaq Last Sale

1.130
0.000
0.00%
已收盘, 16:00 11/21 EST
开盘
1.160
昨收
1.130
最高
1.160
最低
1.070
成交量
10.99万
成交额
--
52周最高
1.950
52周最低
0.8200
市值
6,444.27万
市盈率(TTM)
-1.4660
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INFI 新闻

  • 特斯拉电动皮卡正式发布 特斯拉电动皮卡长这样
  • TechWeb.2小时前
  • 沪指冲高回落 油价触及近两个月高点
  • 新浪财经.2小时前
  • 可口可乐再活130年 离不开这套长期策略
  • 界面.2小时前
  • 特斯拉电动皮卡今日发布 马斯克称将成火星官方用车
  • TechWeb.2小时前

更多

所属板块

生物技术和医学研究
-0.38%
制药与医学研究
+0.29%

热门股票

名称
价格
涨跌幅

INFI 简况

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
展开

Webull提供Infinity Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。